Montalban X, et al. Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients With Primary Progressive Multiple Sclerosis in the ORATORIO Trial. PR2086. EAN 2017.
HRQOL en cognitieve functie na lomustine-temozolomide versus temozolomide
dec 2019 | Neuro-oncologie